IN2014DN09013A - - Google Patents

Info

Publication number
IN2014DN09013A
IN2014DN09013A IN9013DEN2014A IN2014DN09013A IN 2014DN09013 A IN2014DN09013 A IN 2014DN09013A IN 9013DEN2014 A IN9013DEN2014 A IN 9013DEN2014A IN 2014DN09013 A IN2014DN09013 A IN 2014DN09013A
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Xizhong Huang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2014DN09013A publication Critical patent/IN2014DN09013A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN9013DEN2014 2012-03-30 2014-10-28 IN2014DN09013A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261618215P 2012-03-30 2012-03-30
PCT/US2013/034214 WO2013148912A1 (fr) 2012-03-30 2013-03-28 Composés pour utilisation dans le traitement de neuroblastome, sarcome d'ewing ou un rhabdomyosarcome

Publications (1)

Publication Number Publication Date
IN2014DN09013A true IN2014DN09013A (fr) 2015-05-22

Family

ID=48142079

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9013DEN2014 IN2014DN09013A (fr) 2012-03-30 2014-10-28

Country Status (11)

Country Link
US (2) US20150051252A1 (fr)
EP (1) EP2830619A1 (fr)
JP (1) JP2015512416A (fr)
KR (1) KR20150002623A (fr)
CN (1) CN104244949A (fr)
AU (1) AU2013239624A1 (fr)
CA (1) CA2865993A1 (fr)
IN (1) IN2014DN09013A (fr)
MX (1) MX2014011843A (fr)
RU (1) RU2014143232A (fr)
WO (1) WO2013148912A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015078931A1 (fr) * 2013-11-27 2015-06-04 Oncoethix Sa Méthode de traitement de neuroblastomes à l'aide de composés thiénotriazolodiazépine
US10874631B2 (en) 2016-12-21 2020-12-29 The Board Of Regents Of The University Of Texas System Altertoxin II as a selective inhibitor of Ewing family of tumor cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR044519A1 (es) * 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
KR20100093129A (ko) * 2007-12-20 2010-08-24 노파르티스 아게 Pi 3 키나제 억제제로서 사용되는 티아졸 유도체
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
JP5819831B2 (ja) * 2009-08-17 2015-11-24 インテリカイン, エルエルシー 複素環式化合物およびそれらの使用
WO2012175522A1 (fr) * 2011-06-21 2012-12-27 Novartis Ag Polymorphes du 2-amide-1-({4-méthyl-5-[2-(2,2,2-trifluoro-1,1-diméthyl- éthyl)pyridin-4-yl]-thiazol-2-yl}-amide d'acide (s)-pyrrolidine-1,2-dicarboxylique
MX359406B (es) * 2011-07-01 2018-09-27 Novartis Ag Terapia de combinación que comprende un inhibidor de cdk4/6 y un inhibidor de pi3kpara usarse en el tratamiento de cáncer.
US20140235630A1 (en) * 2011-09-30 2014-08-21 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for the treatment of proliferative diseases
US8980259B2 (en) * 2012-07-20 2015-03-17 Novartis Ag Combination therapy

Also Published As

Publication number Publication date
EP2830619A1 (fr) 2015-02-04
CA2865993A1 (fr) 2013-10-03
US20150051252A1 (en) 2015-02-19
RU2014143232A (ru) 2016-05-27
KR20150002623A (ko) 2015-01-07
US20160151344A1 (en) 2016-06-02
JP2015512416A (ja) 2015-04-27
WO2013148912A1 (fr) 2013-10-03
CN104244949A (zh) 2014-12-24
AU2013239624A1 (en) 2014-10-02
MX2014011843A (es) 2014-12-10

Similar Documents

Publication Publication Date Title
BR112014018348A2 (fr)
BR112014017614A2 (fr)
BR112014019228A2 (fr)
BR112014017592A2 (fr)
BR112014017659A2 (fr)
BR112014017646A2 (fr)
AR092201A1 (fr)
BR112014017607A2 (fr)
BR112013027865A2 (fr)
BR112014017609A2 (fr)
BR112014017644A2 (fr)
BR112014017647A2 (fr)
BR112014017588A2 (fr)
BR112014017618A2 (fr)
BR112014013184A8 (fr)
BR112014017652A2 (fr)
BR112014017621A2 (fr)
BR112014019147A2 (fr)
BR112014017667A2 (fr)
BR112014023174A2 (fr)
BR112014017600A2 (fr)
BR112014017671A2 (fr)
BR112014017596A2 (fr)
BR112014017591A2 (fr)
BR112014017589A2 (fr)